Citi initiated coverage of Roche (RHHBY) with a Buy rating and CHF 400 price target The firm cites the company’s improving pipeline for the Buy rating. Royalties on Lilly’s oral orforglipron should also drive growth and margins from Q2 of 2026 for Roche, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- NVDA, GOOGL, AMZN: Trump’s Greenland Gambit Rattles Big Tech as EU Weighs Salvo
- Genentech to more than double East Coast manufacturing plant investment to $2B
- Novartis Stock (NVS) Holds on Upbeat View of Tariff Exposure amid U.S.-EU Tension
- These European Stocks Could Be in the Firing Line in Trump’s Greenland Tariff War
- Trump Trade: White House releases details on ‘Great Healthcare Plan’